Department of Pharmacy, University of Napoli Federico II, Italy
University of Naples Federico II
.jpg)
NAPOLI
////////Friday, 20 November 2015
Francesca Ungaro
University of Naples Federico II
NAPOLI
////////
2nd International conference on Advanced Techniques and Applications of Mass Spectrometry, 19-20 November 2015, Mumbai, India, by SELECTBIO
2nd International conference on Advanced Techniques and Applications of Mass Spectrometry, 19-20 November 2015, at Ramada Powai Hotel and Convention Centre, Mumbai, India, by SELECTBIO
https://selectbiosciences.com/conferences/index.aspx?conf=ATAMS15&se=india
PROF SARANJIT SINGH
Saranjit Singh, Professor/Head, NIPER
Dr Saranjit Singh is
Professor and Head of the Department of Pharmaceutical Analysis at the
National Institute of Pharmaceutical Education and Research (NIPER) at
S.A.S. Nagar, Panjab. He acted as Dean of the institute from July
2008-July 2011. He is Member, Expert Advisory Panel on the International
Pharmacopoeia and Pharmaceutical Preparations, World Health
Organization (WHO), Geneva. He was an invitee member, IARC Monographs
Development Program, International Agency for Research on Cancer, Lyon,
France in 2013. He also acted as a temporary advisor to WHO Expert
Committee on Specifications for Pharmaceutical Preparations between
2007-2010.
Dr Singh is in education and research for the last 32 years. He has published 180 research papers, general articles and book chapters. Till date he has delivered 373 invited lectures at various forums, including AAPS, USP, IPA, IDMA, etc. He is regularly invited to hold full-day training sessions for pharmaceutical industry in India and abroad.
He is a member of Editorial Advisory Board of many journals and reviewer to most of the journals in the area of pharmaceutical analysis.
Dr Singh is recipient of Professor M.L. Khorana Memorial Lecture Award (2005), and IDMA-APA Eminent Analyst (2008) and Outstanding Analyst (2002) Awards.
Dr Singh is in education and research for the last 32 years. He has published 180 research papers, general articles and book chapters. Till date he has delivered 373 invited lectures at various forums, including AAPS, USP, IPA, IDMA, etc. He is regularly invited to hold full-day training sessions for pharmaceutical industry in India and abroad.
He is a member of Editorial Advisory Board of many journals and reviewer to most of the journals in the area of pharmaceutical analysis.
Dr Singh is recipient of Professor M.L. Khorana Memorial Lecture Award (2005), and IDMA-APA Eminent Analyst (2008) and Outstanding Analyst (2002) Awards.
.With Ashraf mahmoud el marsafy, Dr, Prof., Mr Sanjay Bajaj of selectbio and Anthony Melvin Crasto ,Bhawna Madan at Ramada Powai Hotel & Convention Centre
Mr Sanjay Bajaj of selectbio , POOJA and Anthony Melvin Crasto ,Bhawna Madan at Ramada Powai Hotel & Convention Centre
Mrs Zimmer seen in pic holding plate, Anthony Melvin Crasto. AND Mr Markus Zimmer
Mr Markus Zimmer, Head, Analytical Development, Sanofi, in 34184, Montpellier, cedex4, France, Head of “Chemical and Pharmaceutical
Analysis Unit 2”, now responsible for the analytical development of new
chemical entities up to clinical phase 2b.
Markus Zimmer in action
Markus Zimmer, Head, Analytical Development, Sanofi
In 1995, Dr Markus Zimmer
graduated as licensed pharmacist from the University of Saarland in
Saarbrücken/Germany, where he received in 1997 his PhD in Pharmakognosy
and Analytical Phytochemistry.
He worked as an Assistant production manager (WALA/Eckwälden) before joining 1999 the Analytical Sciences Department of Hoechst Marrion Roussel (HMR) – now Sanofi - in Frankfurt/Germany as lab head. In parallel, he completed the qualification as pharmacist specialized in Pharmaceutical Technology (2001) and Pharmaceutical Analytics (2003).
In 2006, Markus Zimmer moved to Sanofi in Montpellier/France as Head of “Chemical and Pharmaceutical Analysis Unit 2”, now responsible for the analytical development of new chemical entities up to clinical phase 2b.
He worked as an Assistant production manager (WALA/Eckwälden) before joining 1999 the Analytical Sciences Department of Hoechst Marrion Roussel (HMR) – now Sanofi - in Frankfurt/Germany as lab head. In parallel, he completed the qualification as pharmacist specialized in Pharmaceutical Technology (2001) and Pharmaceutical Analytics (2003).
In 2006, Markus Zimmer moved to Sanofi in Montpellier/France as Head of “Chemical and Pharmaceutical Analysis Unit 2”, now responsible for the analytical development of new chemical entities up to clinical phase 2b.
Juergen Schaefer, Lab Head, Sanofi
Dr Juergen Schaefer is
currently Laboratory Head for Mass Spectrometry in Analytical Sciences,
Lead Generation to Candidate Realization of Sanofi in Frankfurt. He
received his Ph.D. in Chemistry from Prof. Michael Karas at Johann
Wolfgang Goethe University in Frankfurt (MALDI-TOF-MS) and has about 20
years of experience in Mass Spectrometry of Biopolymers. Since 2000 he
worked in Protein Biomarker Discovery using Proteomics Mass spectrometry
at Proteome Sciences. He developed Quantitative MS-based Techniques
(e.g. TMT, Tandem Mass Tags) for Peptide and Protein Profiling. After
joining Sanofi in 2009, he is mainly responsible for Characterization of
Peptides and Proteins with Mass Spectrometric Tools in combination with
Separation Methods for Analytical Sciences as well as for
Characterization of Monoclonal Antibodies for Bioanalytics &
Formulation in Frankfurt.
Keynote Speakers
 | |  |  |  |  |
 | |
View all Keynote Speakers
Overview
SELECTBIO is pleased to welcome you to its 2nd Annual Conference on “Advanced Techniques & Applications of Mass Spectrometry” scheduled to be held on November 19-20, 2015 at Ramada Powai Hotel and Convention Centre, Mumbai, India.After the successful inaugural conference in IICT, Hyderabad last year, this conference has been conceptualized to discuss the advanced techniques and applications of Mass Spectrometry. The experts in this conference will cover various advanced techniques followed by novel applications of Mass Spectrometry in analysis of Pharmaceutical and Forced Degradation products, Metabolites, Food, Environment, Forensic, Clinical and Biological samples. This event will provide you with excellent opportunity to enhance your knowledge on Mass Spectrometry as well as learn the advanced applications in different fields. Further, this event will also help in networking with like minded peers, helping you to build new relationships and optimize your workflow.
Running alongside the conference will be an exhibition covering the latest technological advances and associated services within this field.
Lab Visit
A Mass Spectrometry Lab Visit and Demonstration in SAIF, IIT Bombay will form an integral part of this event.This SAIF Laboratory houses MS Instruments like LC-MS QTOF, GC-MS QTOF, GC- HRMS, ICP- MS, HR- LCMS, LC-MS, TOF-SIMS etc and will cover demonstration of LCMS QTOF & GCMS QTOF.
Who Should Attend
Scientists and Researchers, Biotechnologists, Medical doctors, Clinicians and Chemists from Academics,Pharmaceutical/Biotechnology/Forensic/Food/Environmental Industries, Laboratories working in the following areas/field :
•Pharmaceutical Analysis, Organic, Analytical & Medicinal Chemistry and Scientists working in Mass Spectrometry and Chromatography Laboratory , Stability Studies, Forced degradation/stress studies in Pharmaceuticals, Formulation Development, Drug Discovery, Biomarker Discovery
•Genomics, Proteomics, Metabolomics & Lipidomics
•Mass Spectrometry for Clinical Diagnosis, Forensic Chemistry, Forensic Sciences, Forensic Medicine and Forensic Toxicology
•Analysis of Food, Dairy Products, Beverages including those engaged in detection of Food Packaging contaminants and Mycotoxins in food samples
•Analysis of Waste water contaminants and Air Pollutants like Pesticides, Perfluorinated compounds and Polyphenolic compounds
International Advisory Board Members
Ruth Andrew, Professor & Chair of Pharmaceutical Endocrinology, University of Edinburgh, UK
Gregori Casals, Scientist, Hospital Clínic Barcelona, Spain
Juergen Gross, Head Mass Spectrometry Lab, Heidelberg University, Germany
Conference Package - Includes Registration and two nights accommodation, (Valid up to November 5, 2015 only)
////////
Thursday, 19 November 2015
Theresa Neumann
-
Clemens Schöpf-Institute of Chemistry and BiochemistryDarmstadt, Hessen, Germany
Clemens Schöpf-Institute of Chemistry and Biochemistry
Darmstadt, Hessen, Germany
Cas 1820758-44-8
C24 H18 F N3 O4 S
4′-((5-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-1,3,4-oxadiazol-2-yl-thio)-methyl)-4-fluorobiphenyl-2-carboxamide
Glycogen synthase kinase-3 (GSK-3) is a constitutively active, ubiquitous serine/threonine kinase that takes part in a number of physiological processes ranging from glycogen metabolism to apoptosis. GSK-3 is a key mediator of various signaling pathways, such as the Wnt and the insulin/AKT signaling pathways.
Therefore, dysregulation of GSK-3 has been linked to various human diseases, such as cancer, diabetes, and neurodegenerative diseases.Two related isoforms of GSK-3 exist in mammals, GSK-3α and -β, which share a sequence identity within their catalytic domains of 98%.
Beyond the catalytic domains they show significant differences. Although these isoforms are structurally related, they are not functionally equivalent, and one cannot compensate for loss of the other.
The debate on the respective contributions of the isoforms GSK-3α and GSK-3β on the pathogenesis of different diseases is ongoing.
Various studies indicate that the therapies of certain diseases benefit from specific targeting of GSK-3α and GSK-3β. GSK-3α was recently identified as a differentiation target in acute myeloid leukemia (AML). AML is a hematopoietic malignancy defined by uncontrolled proliferation and disrupted myeloid differentiation. AML is the second most common form of leukemia in adults.
The current treatment of AML with conventional chemotherapy is very aggressive yet ineffective for the majority of patients with the disease.Thus, alternative targeted treatment approaches for AML are highly desirable. GSK-3α recently emerged as a potential target in this disease.
PAPER
The challenge for glycogen synthase kinase-3 (GSK-3) inhibitor design lies in achieving high selectivity for one isoform over the other. The therapy of certain diseases, such as acute myeloid leukemia (AML), may require α-isoform specific targeting. The scorpion shaped GSK-3 inhibitors developed by our group achieved the highest GSK-3α selectivity reported so far but suffered from insufficient aqueous solubility. This work presents the solubility-driven optimization of our isoform-selective inhibitors using a scorpion shaped lead. Among 15 novel compounds, compound 27 showed high activity against GSK-3α/β with the highest GSK-3α selectivity reported to date. Compound 27 was profiled for bioavailability and toxicity in a zebrafish embryo phenotype assay. Selective GSK-3α targeting in AML cell lines was achieved with compound 27, resulting in a strong differentiation phenotype and colony formation impairment, confirming the potential of GSK-3α inhibition in AML therapy
Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia
† Clemens Schöpf Institute of Organic Chemistry and Biochemistry, Technische Universität Darmstadt, 64287 Darmstadt, Germany
‡ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, United States
J. Med. Chem., Article ASAP
DOI: 10.1021/acs.jmedchem.5b01200
Publication Date (Web): October 23, 2015
Copyright © 2015 American Chemical Society
http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b01200
http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5b01200/suppl_file/jm5b01200_si_001.pdf
compound 27 as a colorless solid. HPLC: 96%, tR = 6.93 min.
1H NMR (DMSO-d6, 500 MHz, 300 K): δ (ppm) = 4.32 (td, J = 5.2 Hz, J = 3.7 Hz, 4H), 4.60 (s, 2H), 7.05 (d, J = 8.4 Hz, 1H), 7.25 (dd, J = 9.1 Hz, J = 2.7 Hz, 1H), 7.31 (td, J = 8.6 Hz, J = 2.8 Hz, 1H), 7.38 (m, 3H), 7.41 (d, J = 2.0 Hz, 1H), 7.45 (dd, J = 8.4 Hz, J = 2.1 Hz, 1H), 7.49 (d, J = 8.2 Hz, 2H), 7.73 (s, 1H).
13C NMR (DMSO, 125 MHz, 300 K): δ (ppm) = 35.6, 64.1, 64.4, 114.3 (d, JC–F = 21 Hz), 115.0, 115.9 (d, JC–F = 21 Hz), 115.9, 118.1, 120.0, 128.6 (2C), 128.8 (2C), 132.0 (d, JC–F = 8 Hz), 134.8, 135.5, 138.9, 139.0 (d, JC–F = 7 Hz), 143.8, 146.7, 160.9 (d, JC–F = 247 Hz), 162.7, 164.9, 169.5.
EI-MS: m/z = 463 (100, [M+]), 464 (26, [M+ + H]), 465 (7, [M+ + 2H].
ABOUT Boris Schmidt
Boris Schmidt
-
Clemens Schöpf-Institute of Chemistry and BiochemistryDarmstadt, Hessen, Germany*Phone: +49 6151 163075. Fax: +49 6151 163278.E-mail: Schmidt_boris@t-online.de.
Boris Schmidt
Boris Schmidt
-
Clemens Schöpf-Institute of Chemistry and BiochemistryDarmstadt, Hessen, Germany*Phone: +49 6151 163075. Fax: +49 6151 163278.E-mail: Schmidt_boris@t-online.de.
-
Medicinal Chemistry
- Molecular mechanisms of neurodegenerative diseases: Alzheimer's disease, BSE
- Protein aggregation: amyloid beta, tau, prions
- Enzyme inhibition: aspartic proteases (Alzheimer's disease), 20 S proteasome (Oncology)
Organic Synthesis
- in Ionic Liquids
- Aromatic heterocycles
- Peptide mimetics
Contact
Darmstadt University of Technology Chemistry
Prof. Dr. Boris Schmidt
L2 | 02,458 Alaric-Weiss-Straße 4 64287 Darmstadt
+49 6151 16-3075
Schmidt_Boris@t-online.de
CV Prof. Schmidt
curriculum vitae
- 1962 Born in San Fernando / Trinidad & Tobago
- 1962-1965 Trinidad and Brazil
- 1982-1989 Chemistry studies at the University of Hannover, Germany and Imperial College, London
- 1991 Doctorate with Prof. HMR Hoffmann at the University of Hannover; Germany
- 1991-94 Teacher at the Uppsala Biomedical Centre, Sweden
- 1993 Postdoc with Prof. KB Sharpless, Scripps Research Institute, La Jolla, California
- 1994-1999 Habilitation for Organic Chemistry at the University of Hannover, Germany
- 1999-2002 Novartis Pharma AG, Basel, Switzerland, Central Nervous System Research
- 2002 Associate (C3) professorship at the Darmstadt University of Technology
Awards
- 1986 Scholarship for the Imperial College, London UK
- 1991 Doctoral Prize of the Hoechst AG
- 1991 PhD: Summa cum laude
- 1992 German Research Foundation Fellowship
- 1994 Uppsala University Fellowship, Sweden
- 2012 Alzheimer's Research Award of Hans and Ilse Breuer Foundation-with T. Misgeld
Memberships
- German Chemical Society
- American Chemical Society
- German Pharmaceutical Society
Cas 1820758-44-8
C24 H18 F N3 O4 S
4′-((5-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-1,3,4-oxadiazol-2-yl-thio)-methyl)-4-fluorobiphenyl-2-carboxamide
Glycogen synthase kinase-3 (GSK-3) is a constitutively active, ubiquitous serine/threonine kinase that takes part in a number of physiological processes ranging from glycogen metabolism to apoptosis. GSK-3 is a key mediator of various signaling pathways, such as the Wnt and the insulin/AKT signaling pathways.
Therefore, dysregulation of GSK-3 has been linked to various human diseases, such as cancer, diabetes, and neurodegenerative diseases.Two related isoforms of GSK-3 exist in mammals, GSK-3α and -β, which share a sequence identity within their catalytic domains of 98%.
Beyond the catalytic domains they show significant differences. Although these isoforms are structurally related, they are not functionally equivalent, and one cannot compensate for loss of the other.
The debate on the respective contributions of the isoforms GSK-3α and GSK-3β on the pathogenesis of different diseases is ongoing.
Various studies indicate that the therapies of certain diseases benefit from specific targeting of GSK-3α and GSK-3β. GSK-3α was recently identified as a differentiation target in acute myeloid leukemia (AML). AML is a hematopoietic malignancy defined by uncontrolled proliferation and disrupted myeloid differentiation. AML is the second most common form of leukemia in adults.
The current treatment of AML with conventional chemotherapy is very aggressive yet ineffective for the majority of patients with the disease.Thus, alternative targeted treatment approaches for AML are highly desirable. GSK-3α recently emerged as a potential target in this disease.
PAPER
The challenge for glycogen synthase kinase-3 (GSK-3) inhibitor design lies in achieving high selectivity for one isoform over the other. The therapy of certain diseases, such as acute myeloid leukemia (AML), may require α-isoform specific targeting. The scorpion shaped GSK-3 inhibitors developed by our group achieved the highest GSK-3α selectivity reported so far but suffered from insufficient aqueous solubility. This work presents the solubility-driven optimization of our isoform-selective inhibitors using a scorpion shaped lead. Among 15 novel compounds, compound 27 showed high activity against GSK-3α/β with the highest GSK-3α selectivity reported to date. Compound 27 was profiled for bioavailability and toxicity in a zebrafish embryo phenotype assay. Selective GSK-3α targeting in AML cell lines was achieved with compound 27, resulting in a strong differentiation phenotype and colony formation impairment, confirming the potential of GSK-3α inhibition in AML therapy
Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia
† Clemens Schöpf Institute of Organic Chemistry and Biochemistry, Technische Universität Darmstadt, 64287 Darmstadt, Germany
‡ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, United States
J. Med. Chem., Article ASAP
DOI: 10.1021/acs.jmedchem.5b01200
Publication Date (Web): October 23, 2015
Copyright © 2015 American Chemical Society
compound 27 as a colorless solid. HPLC: 96%, tR = 6.93 min.
1H NMR (DMSO-d6, 500 MHz, 300 K): δ (ppm) = 4.32 (td, J = 5.2 Hz, J = 3.7 Hz, 4H), 4.60 (s, 2H), 7.05 (d, J = 8.4 Hz, 1H), 7.25 (dd, J = 9.1 Hz, J = 2.7 Hz, 1H), 7.31 (td, J = 8.6 Hz, J = 2.8 Hz, 1H), 7.38 (m, 3H), 7.41 (d, J = 2.0 Hz, 1H), 7.45 (dd, J = 8.4 Hz, J = 2.1 Hz, 1H), 7.49 (d, J = 8.2 Hz, 2H), 7.73 (s, 1H).
13C NMR (DMSO, 125 MHz, 300 K): δ (ppm) = 35.6, 64.1, 64.4, 114.3 (d, JC–F = 21 Hz), 115.0, 115.9 (d, JC–F = 21 Hz), 115.9, 118.1, 120.0, 128.6 (2C), 128.8 (2C), 132.0 (d, JC–F = 8 Hz), 134.8, 135.5, 138.9, 139.0 (d, JC–F = 7 Hz), 143.8, 146.7, 160.9 (d, JC–F = 247 Hz), 162.7, 164.9, 169.5.
EI-MS: m/z = 463 (100, [M+]), 464 (26, [M+ + H]), 465 (7, [M+ + 2H].
Publications in peer reviewed journals
Reaction mechanism, methods, synthesis
| 1. Hoffmann, H. M. R.; Schmidt, B.; Wolff, S. Preparation of 5-Bromotetronates [4-Alkoxy-5-bromo-2(5H)-furanones] and a New Concept for the Synthesis of Aflatoxins and Related Structure Types. Tributyltin Hydride versus Palladium-Promoted Intramolecular Hydroarylation. Tetrahedron, 1989, 45, 6113-6126. |
| 2. Hoffmann, H. M. R.; Schmidt, B. Progress Towards a Convergent and Flexible Synthesis of AFM1. J. Toxicol.-Toxin Reviews, 1989, 8, 299-304 |
| 3. Schmidt, B.; Hoffmann, H. M. R. On the Way to Aflatoxins and Related Structure Types. Regio-controlled Annelations by Application of Homogenous Palladium Catalysis, Urethane Tether and ortho, ortho’-Diiodine Effect. Tetrahedron, 1991, 47, 9357-9368. (IF 3.40) |
| 4. Schmidt, B.; Hoffmann, H. M. R. Regioselective Preparation of Iodinated Phloroglucinols. Chem. Ber.,1992, 125, 1501-1506 |
| 5. Schmidt, B.; Chelidonic Acid as Precursor for 2,5-Desoxy-C-glycosides. Heterocycles, 1999, 51, 179-182 |
| 6. R. Raecker, M. Nicholas, B. Schmidt, O. Reiser; First determination of an activation volume for the osmium-catalyzed dihydroxylation of an alkene. J. Chem. Soc. Perk. Trans 2, 1999, 1615-1617. Räcker, Reinhard; Nicolas, Muriel; Schmidt, Boris; Reiser, Oliver. First determination of an activation volume for the osmium-catalyzed dihydroxylation of an alkene. J. Chem. Soc., Perkin Trans. 2, 1999, 2653 |
| 7. Schmidt, B.; Kühn, C. 2-Mercaptopyridine – Activated Thioates and Ketene Thioacetals. J. Prakt. Chem.1999, 341 (2), 114-120. ttp:www.wiley-vch.de/contents/jc_2258/199902.html |
| 8. H. A. Braun, R. Meusinger, B. Schmidt, 2-Iodoethanols from aldehydes, diiodomethane and isopropyl-magnesium Chloride, Tetrahedron Lett., 2005, 46 (15), 2551-2554 |
| 9. Umbreen, S.; Foro, S.; Schmidt, B., (S)-4-[2-(3-Cyanobenzamido)-3-hydroxypropyl]phenyl 3-cyano-benzoate. Acta Crystallographica, Section E: Structure Reports Online, 2006, 62(6), o2551-2552 |
| 10. Everson da Silva, L.; Joussef, A.C.; Foro, S.; Schmidt, B., 5-(Aminomethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(9), o3866-o3867 |
| 11. Everson da Silva, L.; Joussef, A.C.; Foro, S.; Schmidt, B., 4-n-Propyl-N-(8-quinolyl)benzenesulfonamide. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(9), o3606-o3607 |
| 12. B. Schmidt, D. Meid, D. Kieser, Safe and Fast Tetrazole Formation in Ionic Liquids, Tetrahedron, 2007, 63, 492-496. http://dx.doi |
| 13. A. Zall, D. Bensinger, B. Schmidt, Oxidative homologation of aldehydes to a-ketoaldehydes by iodoform, IBX and dimethylsulfoxide. Eur. J. Org. Chem. 2012 online 24.1.2012 |
Angiotensin II/Peptidomimetics
| 14. Schmidt, B.; Lindman, S.; Tong, W.; Lindeberg, G.; Gogoll, A.; Lai, Z.; Thörnwall, M.; Synnergren, B.;Nilsson, A.; Welch, C. J.; Sohtell, M.; Westerlund, C.; Nyberg, F.; Karlén, A.; Hallberg, A. Design, Synthesis and Biological Activities of Four Angiotensin II Receptor Ligands with ϒ-Turn Mimetics Replacing Amino Acid Residues 3-5. J. Med. Chem, 1997, 40, 903-919. |
| 15. Kühn, C.; Lindeberg, G.; Gogoll, A.; Hallberg, A.; Schmidt, B.; Fmoc Protected Peptide Mimetic Based on a Cyclohexane Framework and Incorporation into Angiotensin II. Tetrahedron, 1997, 53, 12497-12504 |
| 16. Schmidt, B.; Kühn, C.; Racemic, Yet Diasteromerically Pure Azido Acids as Both ϒ-Turn and Inverse ϒ-Turn Mimetics for Solid-Phase Peptide Synthesis, Synlett, 1998, 1240 |
| 17. Schmidt, B.; Patzke G. R. Fmoc-N-allyl Glycine Derived N-Allyl-2,5-diketopiperazines. Synthetic Communications, 1999, 29(6), 1025-1032 |
| 18. B. Schmidt, C. Kühn, D.K. Ehlert, G. Lindeberg, S. Lindman, A. Karlén, A. Hallberg, A Frame Shifted Disulfide Bridged Analogue of Angiotensin II. Bioorg. Med. Chem., 2003, 11, 985-990 |
Sartane metabolism
| 19. Kramer, C., J. Sunkomat, B. Schmidt, B, Schieffer et al.. Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan. Role of the Active Metabolite EXP3179.Circulation Research, 2002, 770-77 |
| 20. B. Schieffer, B. Schmidt, H. Drexler, Angiotensin-II-Rezeptor-unabhängige anti-inflammatorische und antiaggregatorische Eigenschaften von AT1-Antagonisten. Rolle aktiver Metaboliten. Herz BNK, 2003, 28 (7), 2 |
| 21. M. Schupp, L. D. Lee, N. Frost, S. Umbreen, B. Schmidt, T. Unger, U. Kintscher. CHBPR-Regulation of PPARg Activity by Losartan Metabolites. Hypertension, 2006, 47(3), 586-9 |
| 22. C. Grothusen, S. Umbreen, I. Konrad, K. Stellos, C. Schulz, B. Schmidt, E. Kremmer, O. Teebken, S. Massberg, M. Luchtefeld, B. Schieffer*, M. Gawaz. EXP3179 Inhibits Collagen-Dependent Platelet Activation via Glycoprotein Receptor-VI Independent of AT1-Receptor Antagonism. Arteriosclerosis, Thrombosis & Vascular Biology, 2007, 27(5), 1184-1190 |
| 23. L. Danielyan*, A. Lourhmati, S.Verleysdonk, B. Proksch, S.Umbreen, B. Schmidt, C.H. Gleiter. Angiotensin receptor type 1 blockade in astrocytes decreases hypoxia-induced cytotoxicity and inflammation. Neurochemical Research, 2007, 9, 1489-1498. |
| 24. D. Werner, U. Werner, A. Meybaum, B. Schmidt, S. Umbreen, A. Grosch, H. G. Lestin, B. Graf, O. Zolk; M.F. Fromm. Determinants of steady-state torasemide pharmacokinetics: Impact of gender, pharmacogenetic factors and angiotensin II receptor blockers. Clinical Pharmacokinetics, 2008, 47(5), 323-32. (IF 4.12) 20 S Proteasome |
20 S Proteasome
| 25. B. Schmidt, Hannes A. Braun, E-1,2-Dichlorovinyl ethers as irreversible protease inhibitors. Tet. Lett,2004, 45 (8), 1751-1753 |
| 26. H. A. Braun, S. Umbreen, M. Groll, U. Kuckelkorn, I. Mlynarczuk, M. E. Wiegand, I. Drung, P. M. Kloetzel, B. Schmidt. Tripeptide mimetics inhibit the 20S proteasome by covalent bonding to the active site threonines J. Biol Chem, 2005, 280 (31), 28394-28411 |
| 27. I. Mlynarczuk-Bialy, H. Roeckmann, U. Kuckelkorn, B. Schmidt, S. Umbreen, J. Golab, A. Ludwig, C. Montag, L. Wiebusch, C Hagemeier, D. Schadendorf, P.-M. Kloetzel, U. Seifert. Combined Effect of Proteasome and Calpain Inhibition on Cisplatin-Resistant Human Melanoma Cells. Cancer Research, 2006, 66(15), 7598-7605 |
| 28. M.A. Graewert, N. Gallastegui, M. Stein, B. Schmidt, P.-M. Kloetzel, R. Huber, M. Groll. Elucidation of the α-Keto-Aldehyde Binding Mechanism: A Lead Structure Motif for Proteasome Inhibition. Angew. Chemie 2011, 123(2), 563-566, Angew. Chemie IE, 2011, 50(2), 542-546 |
Alzheimer Dementia
| 29. B. Schmidt, A. Zall, G. Larbig, Inhibitors Designed for Presenilin 1 by Means of Aspartic Acid Activation. Helvetica Chimica Acta , 2004, 87, 2334-2340 |
| 30. B. Schmidt, S. Baumann, R. Narlawar, H.A. Braun, G. Larbig. Modulators and Inhibitors of ϒ- and β-Secretase. Neurodegenerative Diseases, 2006, 3(4-5), 290-297 |
| 31. G. Larbig, B. Schmidt. A Facile Synthesis of Tetramic & Tetronic Acids as β-Secretase Inhibitors, J. Combinatorial Chemistry , 2006, 8, 480-490 |
| 32. S. Umbreen, M. Brockhaus, H. Ehrenberg, B. Schmidt. Norstatines from Aldehydes by Sequential Organocatalytic α-Amination and Passerini Reaction. European J. Org. Chem. 2006, 4585-4595 |
| 33. R. Narlawar, K.-H. Baumann, R. Schubenel, B. Schmidt. Curcumin Derivatives inhibit or modulate β-amyloid precursor protein metabolism. Neurodegen. Dis. 2007, 4(2), 88-93 |
| 34. R. Narlawar, B. Perez Revuelta, K. Baumann, R. Schubenel, C. Haass, H. Steiner, B. Schmidt*. N-Substituted Carbazolyloxyacetic Acids Modulate Alzheimer Associated ϒ–Secretase. Biorg. Med. Chem. Lett. 2007, 17(1), 176-182 |
| 35. R. Narlawar, B. Perez Revuelta, C. Haass, H. Steiner, K.-H. Baumann, B. Schmidt*. The Scaffold of the COX-2 Inhibitor Carprofen Provides Alzheimer ϒ-Secretase Modulators. J. Med. Chem. 2006, 49(26), 7588-7591 |
| 36. G. Larbig, M. Pickhardt, D.G. Lloyd, B. Schmidt*, E. Mandelkow. Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: A ligand based approach results in successful scaffold hopping. Current Alzheimer Research 2007, 4(3), 315-323 |
| 37. V. Limongelli, L. Marinelli*, S. Cosconati, H. A. Braun, B. Schmidt, E. Novellino. Ensemble-docking approach on BACE-1: Pharmacophore Perception and Directives for Drug Development. ChemMedChem,2007, 2(5), 667-678 |
| 38. M. Pickhardt, G. Larbig, I. Khlistunova, A. Coksezen, B. Meyer, E-M. Mandelkow, B. Schmidt*, E. Mandelkow*. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry, 2007, 46(35), 10016 -10023 |
| 39. R. Narlawar, K. Baumann, C. Czech, B. Schmidt. Conversion of the LXR-Agonist TO-901317 – From Inverse to Normal Modulation of g-Secretase by Addition of a Carboxylic Acid and a Lipophilic Anchor.Biorg. Med. Chem. Lett. 2007, 17(19), 5428-5431 |
| 40. H. A. Braun, A. Zall, M. Brockhaus, M. Schütz, R. Meusinger, B. Schmidt. Aspartic Protease Inhibitors via C1 -Homologation of Peptidic Aldehydes and Studies on Reduced Amide Isosteres. Tet. Lett. 2007, 48(45) 7990-7993 |
| 41. R. Narlawar, M. Pickhardt, S. Leuchtenberger, K. Baumann, S. Krause, T. Dyrks, S. Weggen, E. Mandelkow, B. Schmidt*. Curcumin Derived Pyrazoles and Isoxazoles – Swiss Army Knives or Blunt Tools for Alzheimer´s Disease? ChemMedChem, 2008, 3, 165-172 |
| 42. T. L. Kukar, T. B. Ladd, M. A. Bann, P. C. Fraering, R. Narlawar, G. M. Maharvi, B. Healy, R.Chapman, A. Welzel, R. W. Price, B. Moore, V. Rangachar, B. Cusack, J. Eriksen, K. Jansen-West, C. Verbeeck, D. Yager, C. Eckman, W. Ye, S. Sagi, B. A. Cottrell, J.Torpey, T. L. Rosenberry, A. Fauq, M. S. Wolfe, B. Schmidt, D. M. Walsh, Edward H. Koo, T.E. Golde. Substrate targeting ϒ-Secretase Modulators. Nature, 2008, 453, 7197 |
| 43. S. Baumann, N. Hoettecke R. Schubenel, K. Baumann, B. Schmidt. NSAID-derived ϒ-secretase modulators. Part III. Membrane anchoring. Biorg. Med. Chem. Lett. 2009, 19 (24), 19, 6986-6990 |
| 44. J. Pruessmeyer, C. Martin, F. M. Hess, N. Schwarz, S. Schmidt, T. Kogel, N. Hoettecke, B. Schmidt, A. Sechi, S. Uhlig, A. Ludwig. A Disintegrin and Metalloproteinase 17 (ADAM17) Mediates Inflammation-induced Shedding of Syndecan-1 and -4 by Lung Epithelial Cells. J. Biol. Chem. 2010, 285(1), 555-564 |
| 45. N. Hoettecke, A. Ludwig, S. Foro, B. Schmidt. Improved Synthesis of ADAM10 Inhibitor GI254023X.Neurodegenerative Diseases, 2010, 7(4), 232-238 |
| 46 N. Hoettecke, M. Liebeck, K. Baumann, R. Schubenel, E. Winkler, H. Steiner, B. Schmidt. Inhibition of ϒ-secretase by the CK1 inhibitor IC261 does not depend on 1d, Biorg. Med. Chem. Lett. 2010, 20(9), 2958-2963 |
| 47. S. Burgold, T. Bittner, M. M. Dorostkar, D.Kieser, M. Fuhrmann, G. Mitteregger, H. Kretzschmar, B. Schmidt, J. Herms. In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks Acta Neuropathologica, 2011, 121, 327-335 |
| 48. F. Lo Monte, T. Kramer, A. Boländer, B. Plotkin, H. Eldar-Finkelman, A. Fuertes, J. Dominguez, B. Schmidt. Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: a fast and atom efficient access to 1-aryl-3-benzylureas. Bioorg. Med. Chem. Lett. 2011, 21(18), 5610-5615 |
| 49. A. Zall, D. Kieser, N. Höttecke, E. C. Naumann, B. Thomaszewski, K. Schneider, D.T. Steinbacher, R. Schubenel, S. Masur, K. Baumann, B. Schmidt. NSAID-derived ϒ-secretase modulation requires an acidic moiety on the carbazole scaffold. Bioorg. Med. Chem. 2011, 19(16), 4903-4911 |
| 50. A. Taghavi, S. Nasir, M. Pickhardt, R. Heyny-von Haußen, G. Mall, E. Mandelkow, E.-M. Mandelkow, B. Schmidt. N'-benzylidene-benzohydrazides as novel and selective tau-PHF ligands. J. Alzheimer’s Disease,2011, 27 (4), 835-843 |
| 51. F. Lo Monte, T. Kramer, J. Gu, U. Anumala, L. Marinelli, V. La Pietra, E. Novellino, B. Franco, D. Demedts, F. Van Leuven, A. Fuertes, J. Dominguez, B. Plotkin, H. Eldar-Finkelman, B. Schmidt.Identification of Glycogen Synthase Kinase-3 Inhibitors with a Selective Sting for Glycogen Synthase Kinase-3α. J. Medicinal Chemistry, 2012, 55 (9), 4407–4424 |
| 52. A. Boländer, D. Kieser, C. Voss, S. Bauer, C. Schön, S. Burgold, T. Bittner, J. Hölzer, R. Heyny-von Haußen, G. Mall, V. Goetschy, C. Czech, H. Knust, R. Berger, J. Herms, I. Hilger, B. Schmidt. Bis(arylvinyl)pyrazines, -pyrimidines and -pyridazines as Imaging Agents for Tau Fibrils and β-Amyloid Plaques in Alzheimer’s Disease Models. J. Med. Chem. 2012, 55 (21), 9170-9180 |
| 53. T. Bittner, S. Burgold, M. M. Dorostkar, M. Fuhrmann, B. M. Wegenast-Braun, B. Schmidt, H. Kretzschmar, J. Herms. Amyloid plaque formation precedes dendritic spine loss. Acta Neuropathologica,2012, 124 (6), 797-808 |
| 54. J. Gu, U. R. Anumala, F. Lo Monte, T. Kramer; R. Heyny-von Haußen, J. Hölzer; V. Goetschy-Meyer; G. Mall, I. Hilger, C. Czech, B. Schmidt. 2-Styrylindolium based fluorescent probes visualize neurofibrillary tangles in Alzheimer's disease. Bioorg. Med. Chem. Lett. 2012, 22 (24), 7667-7671 |
| 55. C. Schön, N.A. Hoffmann, S.M. Ochs, S. Burgold, S. Filser, S. Steinbach, M.W. Seeliger, T. Arzberger, M. Goedert, H.A. Kretzschmar, B.Schmidt, J. Herms. Long-Term In Vivo Imaging of Fibrillar Tau in the Retina of P301S Transgenic Mice. PLoS ONE, 2012, 7(12): e53547. doi:10.1371/journal.pone.0053547 |
| 56. F. Lo Monte, T. Kramer, J. Gu, M. Brodrecht, J. Pilakowski, Ana Fuertes, J. M. Dominguez, B. Plotkin, H. Eldar-Finkelman, B. Schmidt, Structure-based optimization of oxadiazole-based GSK-3 inhibitors.European J. Med. Chem. 2013, 61, 26-40 |
| 57. J. Gu, U.R. Anumala, R. Heyny-von Haußen, J. Hölzer, V. Goetschy-Meyer, G. Mall, I. Hilger, C. Czech, B. Schmidt. Design, Synthesis and Biological Evaluation of Trimethine Cyanine Dyes as Fluorescent Probes for the Detection of Tau Fibrils in Alzheimer´s Disease Brain and Olfactory Epithelium. ChemMedChem,2013, 8, 891-897 |
| 58. A. Boländer, D. Kieser, C. Scholz, R. Heyny-von Haußen, G. Mall, V. Goetschy, C. Czech B. Schmidt. Synthesis of Methoxy-X04 Derivatives and their Evaluation in Alzheimer's Disease Pathology.Neurodegenerative Diseases, 2013, accepted 18.4.2013 |
| 59. E. C. Naumann, S. Göring, I. Ogorek, S. Weggen, B. Schmidt. Membrane anchoring ϒ-secretase modulators with terpene-derived moieties. Bioorg. Med. Chem. Lett. 2013, 23, 3852-3856 |
| 60. |
Trypanosoma
| 61. Luiz Everson da Silva, Antônio Carlos Joussef, Letícia Kramer Pacheco, Daniela Gaspar da Silva, Mário Steindel, Ricardo Andrade Rebelo and Boris Schmidt, Synthesis and in vitro evaluation of leishmanicidal and trypanocidal activities of N-quinolin-8-yl-arylsulfonamides. Bioorg. Med. Chem. 2007, 15, 7553–7560. Cystic fibrosis / protein folding / natural products |
Cystic fibrosis / protein folding / natural products
| 62. Karen Bernard, Wei Wang, Rajeshwar Narlawar, Boris Schmidt, Kevin L. Kirk. Curcumin cross-links cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides and potentiates CFTR channel activity by distinct mechanisms. J. Biol. Chem. 2009, 284, 30754-3076 |
Co-authored ADAM 10 related publications
| 63. Alison M. Cooper, Philip S. Hobson, Mark R. Jutton, Michael W. Kao, Binia Thomaszewski, Boris Schmidt, David J. Fear, Andrew J. Beavil, James M. McDonnell, Brian J. Sutton & Hannah J. Gould. Soluble CD23 Controls IgE Synthesis and Homeostasis in Human B Cells. J. of Immunology, 2012, 188 (7), 3199-3207 |
| 64. V. Lo Sardo, C. Zuccato, G. Gaudenzi, B. Vitali, C. Ramos, M. Tartari, M.A. Myre, J.A. Walker, A. Postocchi, L. Conti, M. Valenza, B. Drung, B. Schmidt, J. Gusella, S. Zeitlin, F. Cotelli, E. Cattaneo. Nature Neuroscience, 2012, An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin, 15 (5), 713-721. (IF 14.19) |
| 65. Q. Xiao, F. Zhang, L. Lin, C. Fang, G. Wen, T.-N. Tsai, X. Pu, D. Sims, Z. Zhang, X. Yin, B. Thomaszewski, B. Schmidt. M. Mayr, K. Suzuki, Q. Xu, S. Ye. A Functional Role of Matrix Metalloproteinase-8 in Stem/Progenitor Cell Migration and Their Recruitment into Atherosclerotic Lesions. Circulation Research,2013, 112, 35 (IF 9.9). |
| 66. Q. Xiao, F. Zhang, G. Grassia, Y. Hu, Z. Zhang, Q. Xing, X. Yin, M. Maddaluno, B. Drung, B. Schmidt, P. Maffia, A. Ialenti, M. Mayr, Q. Xu, S. Ye. Matrix Metalloproteinase-8 Promotes Vascular Smooth Muscle Cell Proliferation and Neointima Formation. Arterioscler. Thromb. Vasc. Biol. 2013, published online October 24 2013, (IF 6.338) doi:10.1161/ATVBAHA.113.301418 |
Kinase inhibition
| 67. Amombo, G. M. O.; Kramer, T.; Lo Monte, F.; et al.. Modification of a promiscuous inhibitor shifts the inhibition from gamma-secretase to FLT-3 . Bioorganic & Medicinal Chemistry Letters, 2012, 22 (24), 7634-7640 |
Metal complexes / X-ray structure determination
| 68. Schmidt, B.; Neitemeier V.; 6-Pyridylnicotine – A New Chiral 2,2’-Bipyridine. Synthesis, 1998, 42. (IF 2.2) |
| 69. Schmidt, B.; Ehlert, D. K.; Preparation of N-Boc-(2,6-bis(ethoxycarbonylpyridiny-4-yl)-L-alanines as tridentate ligands. Tet. Lett. 1998, 39, 3999-4002 |
| 70. G. Muller, B. Schmidt, J. Jiricek, G. Hopfgartner, J.P. Riehl, J.C.G. Buenzli, C. Piguet. Lanthanide triple helical complexes with a chiral ligand derived from 2,6-pyridindicarboxylic acid. J.Chem. Soc., Dalton Trans. 2001, 2658-2665 |
| 71. G. Muller, B. Schmidt; J. Jiricek, J.C.G. Buenzli, K.J. Schenk. 3-[2,6-Bis(diethylcarbamoyl)-pyridin-4-yl]-N-(tert-butoxycarbonyl)alanine methyl ester: a chiral tridentate ligand that causes a diastereomeric excess of its lanthanide complexes in solution. Acta Crystallographica, Section C: Crystal Structure Communications, 2003, 59, 353-356 |
| 72. B. Schmidt, A. Titz, J. Jiricek, Guofeng Ye, K. Parang, Copper dipicolinates as peptidomimetic ligands for the Src SH2 domain. Bioorg. Med. Chem. Lett. 2004, 14 (16), 4203-4206 |
| 73. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 6-Nitroquinolin-2(1H)-one. Acta Crystallographica, Section E: Structure Reports Online, 2005, E61(9), 2992-2993 |
| 74. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 4-Fluoro-N-(quinolin-8-yl)benzenesulfonamide. Acta Crystallographica, Section E: Structure Reports Online, 2005, E61(12), o4387-o4388 |
| 75. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., N-Benzyl-8-nitroquinolin-2-amine. Acta Crystallographica, Section E: Structure Reports Online, 2005, E61(11), o3837-o3838 |
| 76. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., N-(5,7-Dibromo-8-quinolyl)-4-fluorobenzenesulfonamide. Acta Crystallographica, Section E: Structure Reports Online, 2005, E61(11), o3782-o3783 |
| 77. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 2,4,6-Triisopropyl-N-(8-quinolyl)benzenesulfonamide. Acta Crystallographica, Section E: Structure Reports Online, 2005, E61(11), o3780-o3781 |
| 78. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 4-Nitro-N-(8-quinolyl)benzenesulfonamide.Acta Crystallographica, Section E: Structure Reports Online, 2005, E61(11), o3778-o3779 |
| 79. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 5,7-Dibromo-N-tosylquinolin-8-amine. Acta Crystallographica, Section E: Structure Reports Online, 2005, E61(10), o3435-o3436 |
| 80. Everson da Silva, L. E.; Joussef, A. C.; Foro, S.; Schmidt, B., N-(6-Methoxy-2-methyl-8-quinolyl)-4-n-propylbenzenesulfonamide. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(2), o626-o627 |
| 81. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 2,2-Dimethyl-5-[(6-methylpyridin-2-yl-amino)-methylene]-1,3-dioxane-4,6-dione. Acta Crystallographica, Section E: Structure Reports Online,2006, E62(8), o3477-o3478 |
| 82. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 2,2-Dimethyl-5-[(4-p-tolylthiazol-2-ylamino)-methylene]-1,3-dioxane-4,6-dione. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(8), o3215-o3216 |
| 83. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., Bis[N-(5,7-dibromoquinolin-8-yl)-3,5-bis(trifluoro-methyl)benzenesulfonamidato-k2N,N']zinc(II). Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(8), m1901-m1903 |
| 84. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., Aquabis[4-nitro-N-(quinolin-8-yl)benzenesulfonamidato-k2N,N']zinc(II). Acta Crystallographica, Section E: Structure Reports Online,2006, E62(8), m1773-m1775 |
| 85. Everson da Silva, L.; Joussef, A. C.; Silva, L. L.; Foro, S.; Schmidt, B., 4-n-Propyl-N-(8-quinolyl)-benzene-sulfonamide. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(9), o3606-o3607 |
| 86. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., N-(5,7-Dibromo-8-quinolyl)-3,5-difluoro-benzenesulfonamide. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(7), o2630-o2631 |
| 87. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., Bis[4-fluoro-N-(quinolin-8-yl)benzenesulfonamidato-k2N,N']zinc(II) hemihydrate. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(7), m1719-m1721 |
| 88. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., Aquabis[N-(5,7-dibromoquinolin-8-yl)-4-methylbenzenesulfonamidato-k2N,N']zinc(II). Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(6), m1258-m1259 |
| 89. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 5-{[4-(4-Bromophenyl)thiazol-2-yl]amino-methylene}-2,2-dimethyl-1,3-dioxane-4,6-dione. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(5), o1722-o1723 |
| 90. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., Bis[4-n-propyl-N-(8-quinolyl)benzenesulfonamidato-k2N,N']zinc(II) dimethylformamide solvate. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(5), m999-m1001 |
| 91. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., Bis[2,4,6-triisopropyl-N-(quinolin-8-yl)-benzene-sulfonamidato-k2N,N']copper(II). Acta Crystallographica, Section E: Structure Reports Online,2006, E62(4), m912-m913. |
| 92. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 2-(1,3-Benzothiazol-2-yl)quinolin-8-ol. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62, (3), o880-o881 |
| 93. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., Bis[4-nitro-N-(quinolin-8-yl)benzenesulfonamidato-k2N,N'']copper(II). Acta Crystallographica, Section E: Structure Reports Online,2006, E62(3), m518-m519. |
| 94. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., Bis[2,4,6-triisopropyl-N-(quinolin-8-yl)-benzenesulfonamidato-k2N,N']zinc(II). Acta Crystallographica, Section E: Structure Reports Online,2006, E62(3), m516-m517 |
| 95. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 5-[(6-Fluoro-1,3-benzothiazol-2-ylamino)-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione. Acta Crystallographica, Section E: Structure Reports,2006, E62 (2), o742-o743. |
| 96. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 4,5-Dibromo-N-(8-quinolyl)thiophene-2-sulfonamide. Acta Crystallographica, Section E: Structure Reports Online,2006, E62(1), o309-o310 |
| 97. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 2,2-Dimethyl-5-[(6-methylpyridin-2-yl-amino)-methylene]-1,3-dioxane-4,6-dione. Acta Crystallographica, Section E: Structure Reports Online,2006, E62(8), o3477-o3478 |
| 98. E. Ramic, R.-A. Eichel, K.-P. Dinse, A. Titz, B. Schmidt, Complexation of copper(II)-chelidamate – A multi-frequency pulsed Electron Paramagnetic Resonance and Electron Nuclear Double Resonance analysis J. Phys.Chem. 2006, 110(41), 20655-20663 |
| 99. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., Bis[4-fluoro-N-(quinolin-8-yl)benzenesulfonamidato-k2N,N']copper(II) dichloromethane hemisolvate. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(7), m1606-m1608 |
| 100. Everson da Silva, L.; Joussef, A. C.; Rebelo, R.A.; Foro, S.; Schmidt, B., 2-Aminoquinolin-4-yl 2,4,6-triisopropylbenzenesulfonate. Acta Crystallographica, Section E: Structure Reports Online, 2006, E62(7), o5421–o5422. |
| 101. Everson da Silva, L.; Joussef, A. C.; Rebelo, R.A.; Foro, S.; Schmidt, B., 2-Aminoquinolin-8-yl p-toluenesulfonate. Acta Crystallographica, Section E: Structure Reports Online, 2007, E63, o72–o74 |
| 102. Everson da Silva, L.; Joussef, A. C.; Rebelo, R.A.; Foro, S.; Schmidt, B., Aquabis(2-methylquinolin-8-olato-k2N,O)-zinc(II). Acta Crystallographica, Section E: Structure Reports Online, 2007, E63, m129–m132 |
| 103. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., Silva, 2-Aminoquinolin-8-yl-4-fluorobenzenesulfonate. Acta Crystallographica, Section E: Structure Reports Online, 2007, E63(1), o407-o408 |
| 104. Everson da Silva, L.; Joussef, A. C.; Foro, S.; Schmidt, B., 2-Aminoquinolin-8-yl-2,4,6-triisopropylbenzenesulfonate. Acta Crystallographica, Section E: Structure Reports Online, 2007, E63(1), o409-o411 |
| 105. Everson da Silva, L.; Foro, S.; Schmidt, B., 2-Aminoquinolin-8-yl 3,5-difluorobenzenesulfonate. Acta Crystallographica, Section E: Structure Reports Online, 2007, 63(2), o829-o830 |
Reviews in peer reviewed journals/series
| 106. B. Schmidt, Methyltrioxorhenium – From Oxidation and Cyclopropanation to Metathesis. J. Prakt. Chem. 1997, 339, 493-504 |
| 107. B. Schmidt, Aspartic Proteases involved in Alzheimer's disease, ChemBioChem, 2003, 4 (5), 367-378. (Impact factor 2.9) |
| 108. B. Schmidt, B. Schieffer, Angiotensin II AT1 Receptor Antagonists: Clinical Implications of Active Metabolites. J. Med. Chem. 2003, 46, 2261. (Impact factor 5.3) |
| 109. B. Schmidt, H. Drexler, B. Schieffer, Therapeutic Effects of Angiotensin (AT1) Receptor Antagonists: Potential Contribution of Mechanisms Other Than AT1 Receptor Blockade. American Journal of Cardiovascular Drugs, 2004, 4, 361-368 |
| 110. B. Schmidt, R. Narlawar, H. Braun, Drug Development and PET-Diagnostics for Alzheimer's Disease. Current Medicinal Chemistry. 2005, 12, 1677-1695 |
| 111. B. Schmidt, S. Baumann, H.A. Braun, G. Larbig, Inhibitors and Modulators of β- and ϒ-Secretase.Current Topics in Medicinal Chemistry. 2006, 6(4), 377-392 |
| 112. B. Bulic, M. Pickhardt, B. Schmidt, E.M. Mandelkow, H. Waldmann, E. Mandelkow. Development of Tau Aggregation Inhibitors for Alzheimer's Disease. Angew. Chem. Int. Ed. Engl. 2009, 48, 1740 |
| 113. T. Kramer, F. Lo Monte, S. Göring, G.M. Okala Amombo, B. Schmidt, Small molecule kinase inhibitors for LRRK2 and their application to Parkinson´s disease models. ACS Chemical Neuroscience 2012, 3(3), 151-160 |
| 114. T. Kramer, B. Schmidt, F. Lo Monte, International Journal of Alzheimer's Disease, Small-molecule inhibitors of GSK3 – Structural insights and their application to Alzheimer´s disease models, 2012, accepted. 31.1.2012 |
| 115. Schulz, S. Göring, B. Schmidt, C. Hopf, LRRK2 Kinase Inhibitors as New Drugs for Parkinson’s Disease? in Emerging Drugs and Target for Parkinson’s Disease, RSC Drug Discovery Series No. 34, 2013, p. 266-293. Ed. Ana Martinez, Carmen Gil. RSC Publishing, Cambridge, UK. ISBN: 978-1-84973-617-6 |
Monographies, books and other publications
| 116. Schmidt, B. Auf dem Weg zum Aflatoxin M1 und verwandten Strukturen durch homogene Katalyse, Dissertation, Universität Hannover 1991 |
| 117. B. Schmidt, V. Neitemeier, D.K. Ehlert, A. Backhaus-Ehlert, 6-Pyridylnicotines and 2,6-Pyridyl-dicarboxylates for Supramolecular Chemistry, no. 008 “Electronic Conference on Heterocyclic Chemistry 98”: H.S. Rzepa, O. Kappe (Eds), Imperial College Press, 1998, ISBN 81-02-3594-1,http://www.ch.ic.ac.uk/ectoc/echet98/pub/008/index.ht |
| 118. Workshop of Young European Bio-Organic Chemists: Ed.: Ludger A. Wessjohann, Koeln : Prosciencia-Verl.-Buchh., Philipp, 1998, ISBN 3-932265-01-7 |
| 119. Schmidt, B. Biomimetika – Ihre Synthese durch Übergangsmetall-katalysierte Schlüssel-Reaktionen und ihre Anwendung; Habilitationsschrift, Universität Hannover 1998 |
| 120. B. Schmidt, A. Siegler. Aspartic Proteases involved in Alzheimer's disease, Highlights in Bioorganic Chemistry, ed. C. Schmuck, H. Wennemers. ISBN 3-527-30656-0, Wiley-VCH, Weinheim 2004 |
| 121. Schmidt, B. Larbig, G. ChemBioChem, 2004, 5, |
| 122. Schmidt, B. ChemBioChem, 2004, 5, 1153-1154. |
| 123. Schmidt, B. ChemBioChem, 2005, 6, 760-761 |
| 124. B. Schmidt, Proteins – Structure and Function, ChemBioChem, 2006, 7 (4), 702-703 |
| 125. B. Schmidt, The Adrenergic Receptors for the 21st Century, ChemMedChem, 2006, 1 (8), 904 |
| 126. S. Baumann, N. Höttecke, B. Schmidt, gamma-secretase as a target for AD, in Medicinal Chemistry of Alzheimer’s Disease, ed. A. Martinez, Research Signpost, 2008 |
| 127. N. Höttecke, S. Baumann, A. Taghavi, H.A. Braun, B. Schmidt, Drug Development and Diagnostics for Alzheimer's Disease Up to 2008, in: Frontiers in Medicinal Chemistry Vol. 4, Ed.: Atta-ur-Rahman, A.B. Reitz, 2009, pp. 730-766, Bentham Books 2009, ISBN 90-77527-07-9 |
Subscribe to:
Posts (Atom)